Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population

The document "Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population" reviews the cardiovascular risks associated with hormone therapy in transgender individuals. The study found that transgender women (male-to-female) who underwent hormone therapy had a higher risk of cardiovascular events such as strokes and blood clots compared to cisgender women. Transgender men (female-to-male) did not show a significant increase in cardiovascular risk compared to cisgender men, but both groups had an increased risk compared to the general population. The document also discusses the impact of hormone therapy on DNA methylation or RNA transcription, which could lead to changes in metabolic parameters that increase cardiovascular risk. The document concludes by emphasizing the need for future research to obtain data from prospective controlled studies, including larger samples, to improve the knowledge of the cardiovascular effects of hormone therapy.